AN2 Therapeutics $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by AN2 Therapeutics, Inc. of its common stock for up to an aggregate amount of $100 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “ANTX.”
Based in Menlo Park, California, AN2 Therapeutics is a clinical-stage biotechnology company developing treatments for rare, chronic and serious infectious diseases with high unmet needs. Its initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial (NTM) lung disease.
The Davis Polk corporate team included partner Emily Roberts and associates Jonathan Bye and Rong (Fiona) Huang. All members of the Davis Polk team are based in the Northern California office.